Clinical experience with therapeutic vaccines designed for patients with hepatitis

Current Pharmaceutical Design

Volumn 15, Issue 11, 2009, Pages 1159-1171

  Batdelger, Dendev ^a   Dandii, Dorjiin ^b   Dahgwahdorj, Yagaanbuyant ^c   Erdenetsogt, Erdene ^a   Oyunbileg, Janchivyn ^a   Tsend, Navaansodov ^a   Bayarmagnai, Bold ^c   Jirathitikal, Vichai ^d   Bourinbaiar, Aldar S ^d  

^a Ministry of Health   (Mongolia)

^b Monserum LLC   (Mongolia)

^c MONGOLIAN NATIONAL UNIVERSITY OF MEDICAL SCIENCES   (Mongolia)

^d Immunitor USA Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ADENOVIRUS VECTOR; ALPHA INTERFERON; ANTIVIRUS AGENT; AS 02; CDX 2101; CHIRON; CHRONVAC C; CORVAX; CY 1899; DNA VACCINE; ENTECAVIR; EP 2210; EP 2220; EPIGENE; GENHEVACB; GX 110; HEBERIOVAC; HEPATITIS A VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C VACCINE; HEPATITIS VACCINE; HEPAXEN; HEPVAX; HI 8; HSPBCOR; IMMUNOGLOBULIN; INNO 102; LAMIVUDINE; LIPOSOME; MEINYU; PDPSC 18; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEV 2A PEV 2B; PLACEBO; PPWRG 7128; RC 529; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT HEPATITIS B VACCINE; RIBAVIRIN; SCI B VAC; SPI VEC; T LYMPHOCYTE ANTIGEN; TELBIVUDINE; TERCVAX; THIOPENTAL; TYPHOID VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIR 401; VIRUS ENVELOPE PROTEIN; YIC;

ALLOIMMUNIZATION; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS A; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS E; HUMAN; HUMORAL IMMUNITY; INCIDENCE; MONOTHERAPY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION; VIRUS HEPATITIS; VIRUS REPLICATION; VIRUS RESISTANCE;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; DENDRITIC CELLS; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS C; HUMANS; VIRAL VACCINES;

EID: 65649094069     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787846793     Document Type: Review

References (92)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-500.
2. Butt AA. Hepatitis C virus infection: the new global epidemic. Expert Rev Anti Infect Ther 2005; 3: 241-9.
3. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008; 8: 167-78.
4. Dienstag JL, Stevens CE, Bhan AK, Szmuness W. Hepatitis B vaccine administered to chronic carriers of hepatitis b surface antigen. Ann Intern Med 1982; 96: 575-9.
5. Pol S, Driss F, Carnot F, Michel ML, Berthelot P, Brechot C. Efficacy of immunotherapy with vaccination against hepatitis B virus on virus B multiplication. C R Acad Sci III 1993; 316: 688-91.
6. Dikici B, Kalayci AG, Ozgenc F, Bosnak M, Davutoglu M, Ece A, et al. Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection. Pediatr Infect Dis J 2003; 22: 345-9.
7. Yalcin K, Acar M, Degertekin H. Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection 2003; 31: 221-5.
8. Pata C, Yazar A, Konca K, Bilgic G, Eskandari G, Ozturk C. The effect of recombinant hepatitis B vaccine therapy in chronic hepatitis B infection. Turk J Gastroenterol 2002; 13: 6-10.
9. Pol S, Nalpas B, Driss F, Michel ML, Tiollais P, Denis J, et al. Multicenter study group. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001; 34: 917-21.
10. Jung MC, Gruner N, Zachoval R, Schraut W, Gerlach T, Diepolder H, et al. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine 2002; 20: 3598-612.
11. Ren F, Hino K, Yamaguchi Y, Funatsuki K, Hayashi A, Ishiko H, et al. Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection. J Med Virol 2003; 71: 376-84.
12. Horiike N, Md Fazle Akbar S, Ninomiya T, Abe M, Michitaka K, Onji M. Activation and maturation of antigen-presenting dendritic cells during vaccine therapy in patients with chronic hepatitis due to hepatitis B virus. Hepatol Res 2002; 23: 38-47.
13. Ishikawa T, Kakumu S. Use of hepatitis B vaccine for the treatment of chronic hepatitis B. Hepatol Res 2007; 37(Suppl 3): S347-50.
14. Khurelbaatar N, Oyunbileg J, Lkhagwasuren Ts, Nymadawa P, Tedder RS. Vaccine-therapy in hepatitis B virus carriers. Antivir Ther 2004; Abstr 35; 9: H18.
15. Aguilar JC, Lobaina Y, Muzio V, Garcia D, Penton E, Iglesias E, et al. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol 2004; 82: 539-46.
16. Wright TL, Tong MJ, Hsu HH. Phase I study of a potent adjuvanted hepatitis B vaccine (HBV/MF59) for therapy of chronic hepatitis. Hepatology 1999; 30: 421A.
17. Heathcote J, McHutchison J, Lee S, Tong M, Benner K, Minuk G, et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 1999; 30: 531-6.
18. Neefe JR, Chu NR, Mizzen L. CoVal fusions: a therapeutic vaccine platform using heat shock proteins to treat chronic viral infection and cancer. Dev Biol (Basel) 2004; 116: 193-200.
19. Laing P, Bacon A, McCormack B, Gregoriadis G, Frisch B, Schuber F. The 'co-delivery' approach to liposomal vaccines: application to the development of influenza-A and hepatitis-B vaccine candidates. J Liposome Res 2006; 16: 229-35.
20. McKelvie ND, Stratford R, Wu T, Bellaby T, Aldred E, Hughes NJ, et al. Expression of heterologous antigens in Salmonella Typhimurium vaccine vectors using the in vivo-inducible, SPI-2 promoter, ssaG. Vaccine 2004; 22: 3243-55.
21. Depla E, Van der Aa A, Livingston BD, Crimi C, Allosery K, De Brabandere V, et al. Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. J Virol 2008; 82: 435-50.
22. Barry M, Cooper C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin Biol Ther 2007; 7: 1731-7.
23. Vandepapelière P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, et al. The Therapeutic HBV Vaccine Group of Investigators. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007; 25: 8585-97.
24. Safadi R, Israeli E, Papo O, Shibolet O, Melhem A, Bloch A, et al. Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins. Am J Gastroenterol 2003; 98: 2505-15.
25. Israeli E, Safadi R, Melhem A, Pappo O, Shibolet O, Klein A, et al. Induction of oral immune regulation towards liver-extracted proteins for treatment of chronic HBV and HCV hepatitis: results of a phase I clinical trial. Liver Int 2004; 24: 295-307.
26. Xu DZ, Zhao K, Guo LM, Chen XY, Wang HF, Zhang JM, et al. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS ONE 2008; 3: e2565.
27. Yang SH, Lee CG, Park SH, Im SJ, Kim YM, Son JM, et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther 2006; 13: 1110-7.
28. Batdelger D, Dandii D, Jirathitikal V, Bourinbaiar AS. Open label trial of therapeutic hepatitis B vaccine V-5 Immunitor (V5) delivered by oral route. Lett Drug Des Discov 2007; 4: 540-44.
29. Csatary LK, Telegdy L, Gergely P, Bodey B, Bakacs T. Preliminary report of a controlled trial of MTH-68/B virus vaccine treatment in acute B and C hepatitis: a phase II study. Anticancer Res 1998; 18: 1279-82.
30. Csatary LK, Csatary E, Moss RW. Re: Scientific interest in newcastle disease virus is reviving. J Natl Cancer Inst 2000; 92: 493-4.
31. Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008; 134: 1385-95.
32. Yutani S, Yamada A, Yoshida K, Takao Y, Tamura M, Komatsu N, et al. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine 2007; 25: 7429-35.
33. Leroux-Roels G, Batens AH, Desombere I, Van Den Steen B, Vander Stichele C, Maertens G, et al. Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. Hum Vaccin 2005; 1: 61-5.
34. Nevens F, Roskams T, Van Vlierberghe H, Horsmans Y, Sprengers D, Elewaut A, et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 2003; 38: 1289-96.
35. Haller AA, Lauer GM, King TH, Kemmler C, Fiolkoski V, Lu Y, et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine 2007; 25: 1452-63.
36. Sällberg M, Frelin L, Diepolder HM, Jung MC, Mathiesen I, Fons MP, et al. Antiviral effects of therapeutic vaccination with naked DNA delivered by in vivo electroporation in patients with chronic hepatitis C. American Association for the Study of Liver Diseases, Abstract #LB7, San Francisco, Oct 31-Nov4, 2008.
37. Fournillier A, Gerossier E, Evlashev A, Schmitt D, Simon B, Chatel L, et al. An accelerated vaccine schedule with a polyantigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine 2007; 25: 7339-53.
38. Batdelger D, Dandii D, Jirathitikal V, Bourinbaiar AS. Open-label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C. Vaccine 2008; 26: 2733-7.
39. Alvarez-Lajonchere L, Shoukry NH, Grá B, Amador-Cañizares Y, Helle F, Bédard N, et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat 2008 Oct 31.
40. Vajdy M, Selby M, Medina-Selby A, Coit D, Hall J, Tandeske L, et al. Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J Gen Virol 2006; 87: 2253-62.
41. Gowans EJ, Jones KL, Bharadwaj M, Jackson DC. Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus. J Clin Virol 2004; 30: 283-90.
42. Akbar SM, Abe M, Masumoto T, Horiike N, Onji M. Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells. J Hepatol 1999; 30: 755-64.
43. Zheng BJ, Zhou J, Qu D, Siu KL, Lam TW, Lo HY, et al. Selective functional deficit in dendritic cell - T cell interaction is a crucial mechanism in chronic hepatitis B virus infection. J Viral Hepat 2004; 11: 217-24
44. Akbar SM, Furukawa S, Hasebe A, Horiike N, Michitaka K, Onji M. Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carriers. Int J Mol Med 2004; 14: 295-9.
45. Encke J, Findeklee J, Geib J, Pfaff E, Stremmel W. Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection. Clin Exp Immunol 2005; 142: 362-9.
46. Kuzushita N, Gregory SH, Monti NA, Carlson R, Gehring S, Wands JR. Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens. Gastroenterology 2006; 130: 453-64.
47. Li W, Krishnadas DK, Li J, Tyrrell DL, Agrawal B. Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immunotherapy. J Immunol 2006; 176: 6065-75.
48. Yu H, Babiuk LA, van Drunen Littel-van den Hurk S. Strategies for loading dendritic cells with hepatitis C NS5a antigen and inducing protective immunity. J Viral Hepat 2008; 15: 459-70.
49. Fazle Akbar SM, Furukawa S, Onji M, Murata Y, Niya T, Kanno S, et al. Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers. Hepatol Res 2004; 29: 136-141.
50. Chen M, Li YG, Zhang DZ, Wang ZY, Zeng WQ, Shi XF, et al. Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study. World J Gastroenterol 2005; 11: 1806-8.
51. Duan XZ, He HX, Zhuang H. Restoration in vitro of impaired T-cell responses in patients with chronic hepatitis B by autologous dendritic cells loaded with hepatitis B virus proteins (R2). J Gastroenterol Hepatol 2006; 21: 970-6.
52. Verkade MA, van de Wetering J, Klepper M, Vaessen LM, Weimar W, Betjes MG. Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients. Kidney Int 2004; 66: 614-21.
53. Shi M, Fu J, Shi F, Zhang B, Tang Z, Zhang Z, et al. Viral suppression correlates with dendritic cell restoration in chronic hepatitis B patients with autologous cytokine-induced killer cell transfusion. Liver Int 2008 Aug 14. [Epub ahead of print]
54. Shimizu Y, Guidotti LG, Fowler P, Chisari FV. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol 1998; 161: 4520-9.
55. Mason HS, Lam DM, Arntzen CJ. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci USA 1992; 89: 11745-9.
56. Thanavala Y, Mahoney M, Pal S, Scott A, Richter L, Natarajan N, et al. Immunogenicity in humans of an edible vaccine for hepatitis B. Proc Natl Acad Sci USA 2005; 102: 3378-82.
57. The story of the Mongols whom we call the Tartars (Historia Mongalorum quos nos Tartaros appellamus): Friar Giovanni Di Plano Carpini's Account of His Embassy to the Court of the Mongol Khan. Translated by Erik Hildinger, Branden Publishing Company: Boston, MA1996.
58. Ligon BL. Plague: a review of its history and potential as a biological weapon. Semin Pediatr Infect Dis 2006; 17: 161-70.
59. Silin DS, Lyubomska OV, Jirathitikal V, Bourinbaiar AS. Oral vaccination: where we are? Expert Opin Drug Deliv 2007; 4: 323-40.
60. Ali SM, El-Zawawy LA, El-Said D, Gaafar MR. Immunization against trichinellosis using microwaved larvae of Trichinela spiralis. J Egypt Soc Parasitol 2007; 37: 121-33.
61. Noureldin MS. Oral immunization of mice against Schistosoma mansoni using drinking water from trays containing Biomphalaria alexandrina infected with Schistosoma mansoni. J Egypt Soc Parasitol 1999; 29: 167-77.
62. Heath AW, Arfsten A, Yamanaka M, Dryden MW, Dale B. Vaccination against the cat flea Ctenocephalides felis felis. Parasite Immunol 1994; 16: 187-91.
63. Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 1967; 66: 924-31.
64. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
65. Thimme R, Neumann-Haefelin C, Boettler T, Blum HE. Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine. Biol Chem 2008; 389: 457-67.
66. Vickery K, Tohidi-Esfahani R, Pouliopoulos J, Welschinger R, Dixon R, Deva A, et al. The effect of surgical immunomodulation on liver inflammation and clearance of DHBV infection. J Med Virol 2006; 78: 1572-8.
67. Leroy V, Vigan I, Mosnier JF, Dufeu-Duchesne T, Pernollet M, Zarski JP, et al. Phenotypic and functional characterization of intrahepatic T lymphocytes during chronic hepatitis C. Hepatology 2003; 38: 829-41.
68. Ichiki Y, He XS, Shimoda S, Ishibashi H, Keeffe EB, Rossaro L, et al. T cell immunity in hepatitis B and hepatitis C virus infection: implications for autoimmunity. Autoimmun Rev 2005; 4: 82-95.
69. Guidotti LG, Chisari FV. To kill or to cure: options in host defense against viral infection. Curr Opin Immunol 1996; 8: 478-83.
70. Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transplant 2006; 12: 51-7.
71. Malaguarnera M, Restuccia S, Motta M, Ruello P, Trovato BA, Pistone G. Interferon, cortisone, and antivirals in the treatment of chronic viral hepatitis: a review of 30 years of therapy. Pharmacotherapy 1997; 17: 998-1005.
72. Menne S, Cote PJ, Butler SD, Toshkov IA, Gerin JL, Tennant BC. Immunosuppression reactivates viral replication long after resolution of woodchuck hepatitis virus infection. Hepatology 2007; 45: 614-22.
73. Ilan Y, Chowdhury JR. Induction of tolerance to hepatitis B virus: can we 'eat the disease' and live with the virus? Med Hypotheses 1999; 52: 505-9.
74. Levy L, Ilan Y. Oral immune regulation: a new mode of therapy against chronic viral infections. Recent Patents Anti-Infect Drug Disc 2007; 2: 217-21.
75. Barin F, André M, Goudeau A, Coursaget P, Maupas P. Large scale purification of hepatitis B surface antigen (HBsAg). Ann Microbiol (Paris) 1978; 129B: 87-100.
76. Hilleman MR, McAleer WJ, Buynak EB, McLean AA. The preparation and safety of hepatitis B vaccine. J Infect 1983; 7 Suppl 1: 3-8.
77. Prince AM, Vnek J, Brotman B. An affordable multideterminant plasma-derived hepatitis B virus vaccine. IARC Sci Publ 1984; 63: 355-72.
78. Adamowicz P, Chabanier G, Hyafil F, Lucas G, Prunet P, Reculard P, et al. Elimination of serum proteins and potential virus contaminants during hepatitis B vaccine preparation. Vaccine 1984; 2: 209-14.
79. Alberú J, Morales-Buenrostro LE, de Leo C, Vargas-Rojas MI, Marino-Vázquez LA, Crispín JC. A non-allogeneic stimulus triggers the production of de novo HLA antibodies in healthy adults. Transplant Immunol 2007; 18: 166-71.
80. Miller DS, Halpern M, Kotlarski I, Jilbert AR. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection. Virology 2006; 348: 297-308.
81. Stott EJ. Anti-cell antibody in macaques. Nature 1991; 353: 393.
82. Mei Y, Wang Y, Xu L. Suppression of immune-mediated liver injury after vaccination with attenuated pathogenic cells. Immunol Lett 2007; 110: 29-35.
83. Lindemann M, Barsegian V, Runde V, Fiedler M, Heermann KH, Schaefer UW, et al. Transfer of humoral and cellular hepatitis B immunity by allogeneic hematopoietic cell transplantation. Transplantation 2003; 75: 833-8.
84. Bain C, Fatmi A, Zoulim F, Zarski JP, Trépo C, Inchauspé G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 2001; 120: 512-24.
85. Longman RS, Talal AH, Jacobson IM, Rice CM, Albert ML. Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J Infect Dis 2005; 192: 497-503.
86. Anderson RC, Elder JB, Brown MD, Mandigo CE, Parsa AT, Kim PD, et al. Changes in the immunologic phenotype of human malignant glioma cells after passaging in vitro. Clin Immunol 2002; 102: 84-95.
87. Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani A, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion. Hepatology 2008; 48: 759-69.
88. Nakamoto N, Kaplan DE, Coleclough J, Li Y, Valiga ME, Kaminski M, et al. Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 2008; 134: 1927-37.
89. Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale G, et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006; 80: 11398-403.
90. Kido M, Watanabe N, Okazaki T, Akamatsu T, Tanaka J, Saga K, et al. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology 2008; 135: 1333-43.
91. Pol S. Natural history of hepatitis B infection. Presse Med 2006; 35: 308-16.
92. Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol 2008; 128: 133-47.